151 related articles for article (PubMed ID: 25606414)
1. ABCB1 C3435T and CYP2C19*2 polymorphisms in a Palestinian and Turkish population: A pharmacogenetic perspective to clopidogrel.
Nassar S; Amro O; Abu-Rmaileh H; Alshaer I; Korachi M; Ayesh S
Meta Gene; 2014 Dec; 2():314-9. PubMed ID: 25606414
[TBL] [Abstract][Full Text] [Related]
2. Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention.
Saiz-Rodríguez M; Belmonte C; Caniego JL; Koller D; Zubiaur P; Bárcena E; Romero-Palacián D; Eugene AR; Ochoa D; Abad-Santos F
Clin Ther; 2019 Jun; 41(6):1199-1212.e2. PubMed ID: 31128980
[TBL] [Abstract][Full Text] [Related]
3. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
[TBL] [Abstract][Full Text] [Related]
4. Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel.
Galeazzi R; Olivieri F; Spazzafumo L; Rose G; Montesanto A; Giovagnetti S; Cecchini S; Malatesta G; Di Pillo R; Antonicelli R
Drugs Aging; 2018 Jul; 35(7):649-656. PubMed ID: 29936693
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
Wang XQ; Shen CL; Wang BN; Huang XH; Hu ZL; Li J
Gene; 2015 Mar; 558(2):200-7. PubMed ID: 25542807
[TBL] [Abstract][Full Text] [Related]
6. No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting.
Jaitner J; Morath T; Byrne RA; Braun S; Gebhard D; Bernlochner I; Schulz S; Mehilli J; Schömig A; Koch W; Kastrati A; Sibbing D
Circ Cardiovasc Interv; 2012 Feb; 5(1):82-8, S1-2. PubMed ID: 22298798
[TBL] [Abstract][Full Text] [Related]
7. The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
Saydam F; Değirmenci İ; Birdane A; Özdemir M; Ulus T; Özbayer C; Çolak E; Ata N; Güneş HV
Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):29-36. PubMed ID: 28135763
[TBL] [Abstract][Full Text] [Related]
8. [Genetic and non-genetic factors of laboratory resistance to clopidogrel in patients with ischemic stroke].
Sychev DA; Shprakh VV; Kitaeva EY; Mirzaev KB; Mickhalevich IM
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(3. Vyp. 2):45-52. PubMed ID: 31184624
[TBL] [Abstract][Full Text] [Related]
9. Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial.
Pan Y; Chen W; Wang Y; Li H; Johnston SC; Simon T; Zhao X; Liu L; Wang D; Meng X; Wang Y;
JAMA Neurol; 2019 May; 76(5):552-560. PubMed ID: 30742211
[TBL] [Abstract][Full Text] [Related]
10. [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
Zhou CF; Ren YH; Song YQ; Yi J; Han BS; Xue Q; Fu ZH; Li DY
Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):309-14. PubMed ID: 27112608
[TBL] [Abstract][Full Text] [Related]
11. The clinical effects of CYP2C19 *2 allele frequency on Palestinian patients receiving clopidogrel after percutaneous coronary intervention.
Ayesh BM; Al-Astal IR; Yassin MM
Int J Clin Pharm; 2019 Feb; 41(1):96-103. PubMed ID: 30656556
[TBL] [Abstract][Full Text] [Related]
12. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
Braun OÖ; Angiolillo DJ; Ferreiro JL; Jakubowski JA; Winters KJ; Effron MB; Duvvuru S; Costigan TM; Sundseth S; Walker JR; Saucedo JF; Kleiman NS; Varenhorst C
Thromb Haemost; 2013 Dec; 110(6):1223-31. PubMed ID: 24009042
[TBL] [Abstract][Full Text] [Related]
13. The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease.
Xie C; Ding X; Gao J; Wang H; Hang Y; Zhang H; Zhang J; Jiang B; Miao L
Pharmacogenet Genomics; 2014 Apr; 24(4):204-10. PubMed ID: 24535487
[TBL] [Abstract][Full Text] [Related]
14. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.
Harmsze A; van Werkum JW; Bouman HJ; Ruven HJ; Breet NJ; Ten Berg JM; Hackeng CM; Tjoeng MM; Klungel OH; de Boer A; Deneer VH
Pharmacogenet Genomics; 2010 Jan; 20(1):18-25. PubMed ID: 19934793
[TBL] [Abstract][Full Text] [Related]
15. Distribution of polymorphisms in the CYP2C19 and ABCB1 genes among patients with acute coronary syndrome in Lower Silesian population.
Wójcik T; Szymkiewicz P; Wiśniewski J; Lebioda A; Jonkisz A; Gamian A; Kuliczkowski W; Ściborski K; Mysiak A; Protasiewicz M
Adv Clin Exp Med; 2019 Dec; 28(12):1621-1626. PubMed ID: 31778598
[TBL] [Abstract][Full Text] [Related]
16. Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response.
Han Y; Lv HH; Liu X; Dong Q; Yang XL; Li SX; Wu S; Jiang JM; Luo Z; Zhu DS; Zhang Y; Zheng Y; Guan YT; Xu JF
CNS Neurosci Ther; 2015 Sep; 21(9):692-7. PubMed ID: 26177117
[TBL] [Abstract][Full Text] [Related]
17. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study.
Price MJ; Murray SS; Angiolillo DJ; Lillie E; Smith EN; Tisch RL; Schork NJ; Teirstein PS; Topol EJ;
J Am Coll Cardiol; 2012 May; 59(22):1928-37. PubMed ID: 22624833
[TBL] [Abstract][Full Text] [Related]
18. Role of genetic factors on the effect of additional loading doses and two maintenance doses used to overcome clopidogrel hyporesponsiveness.
Latkovskis G; Urtane I; Knipse A; Peculis R; Cakstina I; Klovins J; Erglis A
Medicina (Kaunas); 2014; 50(1):19-27. PubMed ID: 25060201
[TBL] [Abstract][Full Text] [Related]
19. Genetic and nongenetic factors influencing the response to clopidogrel.
Notarangelo MF; Bontardelli F; Merlini PA
J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S1-7. PubMed ID: 24378836
[TBL] [Abstract][Full Text] [Related]
20. Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients.
Marchini JF; Pinto MR; Novaes GC; Badran AV; Pavão RB; Figueiredo GL; Lago IM; Lima-Filho MO; Lemos DC; Tonani M; Antloga CM; Oliveira L; Lorenzi JC; Marin-Neto JA
Braz J Med Biol Res; 2017 Jan; 50(1):e5660. PubMed ID: 28076455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
